Rocket Lab stock falls 10.8% to $45.44 as its Neutron delay meets a tech rout
Rocket Lab (RKLB) fell 10.8% to $45.44 on November 20, extending a six-day loss of 22.9%. The decline coincided with a broader tech rout but was exacerbated by a delay in Neutron rocket's debut to 2027. Despite strong Q3 revenue growth and a substantial backlog, the company reported adjusted losses and guided to further losses in Q4. Investors are divided on the stock's valuation, which is now 70% below its 52-week high.
How this was made

The 30-second read
Why it matters
The market is likely repricing the timing and probability of Neutron becoming a recurring revenue engine, while still acknowledging near-term support from Electron launches and a growing backlog.
Market read
A single-company execution update (Neutron schedule) is driving a large single-day drawdown, making the next testing milestone a key near-term trading catalyst.
What to watch
The article emphasizes Neutron delays but gives less detail on Electron performance, customer acceptance, and whether manufacturing fixes reduce the probability of a third slip beyond the tank-testing timeline.
Background
Neutron, Rocket Lab’s medium-lift rocket intended to compete with Falcon 9, has already been pushed once and is now described as no earlier than 2027 due to manufacturing issues in the first-stage propellant tank dome.
Ticker impact
Rocket Lab shares fell 10.79% after Neutron’s debut slipped to no earlier than 2027, with manufacturing voids delaying tank completion.
Likely further downside or high volatility as investors reprice the probability of additional Neutron delays and watch the next tank-testing milestone.
The article ties the stock’s sharp drop to Neutron’s delayed debut and highlights a recurring failure mode in the same tank component, which directly undermines the valuation built on Neutron execution.
Market effects
Reinforces risk premium for launch providers tied to next-generation vehicles, where schedule slippage can overwhelm backlog optimism.
Limited direct regional spillover; primarily affects US-listed space/defense growth sentiment.
Global space launch demand remains supported by backlog, but execution risk can tighten financing and raise hurdle rates for next-gen programs.
Counterpoint
Backlog growth, higher Neutron pricing, and Q4 revenue guidance above consensus suggest demand strength that could offset execution risk if testing stays on track into 1Q 2027.
Key entities
- companyRocket Lab
US-listed launch provider whose Neutron debut timing and Q3 financials are central to the stock move.
- programNeutron
Rocket Lab’s medium-lift rocket whose first launch has slipped to no earlier than 2027 due to tank dome voids and testing delays.
- data sourcesGuruFocus and Trefis
Cited for the stock’s recent performance metrics and losing-streak estimate.





